Tele: 561.316.3330
Breaking Medical Device News

Thursday, September 23, 2021
HomeEndologixEndologix Reports Positive Clinical Data from the Ovation LUCY

Endologix Reports Positive Clinical Data from the Ovation LUCY

 

The LUCY study was led by an advisory board whose members include: Chairperson Jennifer Ash, MD, Christie Clinic Vein and Vascular Center and Assistant Clinical Professor of Surgery, University of Illinois College of Medicine in Champaign; Venita Chandra, MD, Clinical Assistant Professor of Surgery-Vascular Surgery, Stanford School of Medicine; Monica Hunter, MD, Birmingham Heart Clinic at St. Vincent’s Birmingham; Eva Rzucidlo, MD, McLeod Vascular and Associate Professor of Surgery, Geisel School of Medicine, Dartmouth; and Ageliki Vouyouka, MD, Associate Professor of Surgery and Radiology, Mount Sinai Hospital.

Endologix, Inc. (Nasdaq:ELGX), today announced 30-day results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair) study. The data showed that at least 28% more women became eligible for minimally-invasive endovascular aneurysm repair (EVAR) when using the Ovation® Abdominal Stent Graft System. The Ovation System is designed to better suit female anatomy than traditional EVAR options and demonstrated lower mortality and complications when compared to previous EVAR studies. The LUCY study is the first to specifically evaluate EVAR outcomes in women, who have historically been underrepresented in EVAR clinical trials.

Recent clinical articles in The Lancet and the Journal of Vascular Surgery indicate that aneurysms grow faster in women than men, leading to a higher rate of rupture and death. Female anatomy may also be more challenging for most commercial EVAR treatments, leading to less eligibility for EVAR and greater mortality, major complications, and readmissions, when compared to men.

Results of the 30-day LUCY data showed that, in women, the ultra-low profile (14F) Ovation device resulted in:

  • At least 28% greater EVAR eligibility for women with AAA
  • 1.3% major adverse events, the lowest rate reported for EVAR, compared to other contemporary, prospective, post-market registries
  • No deaths
  • No proximal endoleaks
  • No limb occlusion
  • Low readmission rate of 3.9%
  • 100% procedural success

Marc Schermerhorn, MD, Associate Professor of Surgery, Beth Israel Deaconess Medical Center, said, “Analysis of historical EVAR clinical data is showing us a large unmet need for AAA treatments for women. Women are less prone to develop the disease, but, when they do, they have significantly worse outcomes than men. New treatment options that better accommodate female anatomy, thereby increasing access and improving outcomes, may go a long way in rectifying the gender disparity in AAA treatment.”

“It is gratifying to see better early outcomes for women in the LUCY study. The Ovation device was able to accommodate the particular challenges of female anatomy, such as small access vessel diameter, short neck length, and higher neck angulation. In addition, mortality, major adverse events, and readmissions were improved for both sexes,” said Venita Chandra, MD, Clinical Assistant Professor of Surgery-Vascular Surgery, Stanford School of Medicine.”  Chandra concluded,  “I look forward to assessing the durability of these results over the longer term.”

The LUCY study is a prospective, consecutively enrolling, non-randomized, multi-center, post-market registry evaluating the Ovation Platform for the endovascular treatment of AAA in women. The study enrolled a total of 225 patients, including 76 females in the treatment group and 149 males in the control group, at 39 sites in the U.S. The primary endpoint of the study was the 30-day Major Adverse Event (“MAE”) rate. Longer-term data from the LUCY study will be shared after the one-year follow-up.

“We are very pleased with the early LUCY study results, which demonstrate the potential Ovation offers to enable more effective treatment of female AAA patients and significantly improved outcomes for all patients,” said John McDermott, Chief Executive Officer of Endologix.  He went on to say, “We look forward to expanding Ovation’s access to more women in those regions where it is available, and to educating both the clinical community and patients about the unique needs of the female patient and the treatment options that are optimized for them.”

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy